Medication info
Levomos 5/40 mg

Levomos 5/40 mg

Prescription medication
Ingredient · strength
Olmesartan Medoxomil›Strength being verifiedS-Amlodipine Besylate 2.5 Hydrate›Strength being verified
Manufacturer / importer
Ahn-Guk Pharmaceutical Co., Ltd.
Appearance
Reddish-brown round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201405839 · Approved 2014.12.10 · Insurance code 650204260

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who uses it
Adults · Children
Adult dosage
Administer 1 tablet once daily with water, regardless of meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine [amlodipine] or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Children's dosage
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Ahn-Guk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

S-Amlodipine or Olmesartan Medoxomil monotherapy is used for adequate blood pressure control in patients with essential hypertension. These medications help lower blood pressure and prevent cardiovascular complications. They effectively stabilize blood pressure even when control is difficult, thus playing an important role in managing essential hypertension.

Dosage and Administration

Adult dosage

Administer 1 tablet once daily with water, regardless of meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine [amlodipine] or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Children's dosage

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and neonate when taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. It is contraindicated in individuals allergic to this medication or its components, pregnant or breastfeeding women, patients with severe liver disease or aortic stenosis, patients with bile duct obstruction, patients on dialysis, shock state patients, and certain diabetic patients. In hypotensive patients with inadequate fluid or salt, there may be a risk of hypotension upon initial use, and their condition should be closely monitored. Appropriate measures should be taken if blood pressure decreases too much. Because of the possibility of rapid vascular dilation leading to hypotension, it should be used cautiously in patients with aortic stenosis, obstructive coronary artery disease, or congestive heart failure. Patients with impaired renal function may experience further deterioration of kidney function, and caution is advised for patients with impaired liver function as well. While taking this medication, various side effects such as dizziness, headache, hypotension, edema, dyspepsia, rash, etc., may occur. If any abnormal symptoms arise, consultation with healthcare professionals is important. In particular, it is advisable to avoid taking this medication with grapefruit juice as this can lead to excessive blood pressure-lowering effects. Women who are pregnant or planning to become pregnant are recommended to switch to other antihypertensive medications that have demonstrated safety instead of this drug. Women who are breastfeeding should discontinue either breastfeeding or this medication, as there is a possibility that it may be transmitted through breast milk and affect the infant. It is not advisable to use this medication in children under 18 years of age, as its safety and efficacy have not been established. Older adults may experience decreased liver, kidney, and heart function, so they should start with a low dose and be prescribed with caution. In case of overdose, hypotension and cardiac arrhythmias may occur, requiring immediate treatment and blood pressure monitoring. This medication should be stored in a tightly closed container to prevent exposure to light and moisture, and kept out of reach of children. Transfers to other containers should be avoided.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, sensory impairment, syncope, vertigo, palpitations, tachycardia, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle tension, limb pain, back pain, frequent urination, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin and hematocrit, back pain, bronchitis, increased creatine kinase, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, asthenia, angioedema, chronic malabsorption-like intestinal disease, intestinal vascular edema, rhabdomyolysis, acute renal failure, hair loss, itching, autoimmune hepatitis, flushing, abdominal pain, nausea, gynecomastia, jaundice, liver enzyme elevation, leukopenia, thrombocytopenia, toxic epidermal necrolysis, significant peripheral vasodilation, tachycardia, bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering and kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's efficacy for a longer period.

Appearance and packaging

Appearance

Reddish-brown round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.